Collagen is a major structure protein found in almost all human tissue. Degraded collagen is present in damaged tissues and is highly associated with many critical human diseases and injuries.
The collagen hybridizing peptide (CHP) can bind to these degraded collagens without affecting intact collagen. The proposed CHP has a high affinity to denatured collagen molecules for use in imaging, diagnosing, and treating diseases and injuries that cause collagen damage. The presence of Aza-Glycine residues from collagen mimetic peptide sequence increases stability of bonding to degraded collagen. The peptide can be paired with existing diagnostics and therapeutic agents to provide highly specific and targeted delivery of therapeutics or imaging markers to damaged collagen. Potential applications range from treating cancer to stabilizing blood clots and treating skin conditions.